Recall: Hospira, Inc. Hydromorphone HCL Injection, USP
On 2018-03-05, the FDA announced that Hospira is conducting a recall on Hydromorphone HCL Injection, USP due to a possible lack of sterility. The recalled products were sold under the brand name(s) Hospira and Inc. during an unspecified time period throughout the regions shown in the map below.
In recent months, there have been 5 drugs recalls due to potential lack of sterility, including labetalol hydrochloride injection, usp, sterile eye irrigation solution and more. Additionally, there have been 17 drug and medical device recalls due to other health hazards as well as 76 food recalls.
Company Contact Information:
Do you work for a company involved with this recall? Contact us to learn how you can control data, information and ads shown on this page.
Detailed Recall Information
Regions Where Sold: Because the region was not specified, it is assumed that this product was available nationwide.
Product Description: Hydromorphone HCL Injection, USP
Brand Name(s): Hospira, Inc.
Reason for Recall: Lack of Sterility
Official Recall Date: 2018-03-05
Additional information provided by the FDA.gov:
Hospira, Inc., a Pfizer company, is voluntarily recalling three lots of Hydromorphone HCl Injection, USP CII 10 mg/mL, 1 mL in 2 mL Single Dose Vials lot numbers 71330DD (NDC 0409-2634-01), and 691853F and 700753F (NDC 0703-0110-01 - Teva lots) to the hospital/institution level. Hospira, Inc. initiated this recall on February 07, 2018 due to the potential that units from these lots may be empty or cracked at the bottom of the glass vial. Read More.
More information may be available at FDA.gov
Latest Safety Recalls
Select image for details, including additional styles.
Sources may include Food & Drug Administration (FDA), United States Department of Agriculture (USDA), Health Canada and companies involved with this or a related recall.